Date: 2015-09-01
Type of information: Series B financing round
Company: Intellia Therapeutics (USA - MA)
Investors: OrbiMed (USA - NY) Fidelity Biosciences (USA - MA) Management and Research Company (USA - CA) Janus Capital Management (USA - CO) Foresite Capital (USA - NY) Sectoral Asset Management (Canada) EcoR1 Capital (USA - CA) Atlas Venture (USA - MA) Novartis (Switzerland)
Amount: $70 Million
Funding type: series B financing round
Planned used: Intellia Therapeutics is a leading gene-editing company focused on the development of proprietary products utilizing the recently discovered CRISPR/Cas9 technology. The company is focused on the development of proprietary human therapeutics using the CRISPR/Cas9 technology to create a potential new drug class with broad in vivo and ex vivo applications. The company intends to use the proceeds to accelerate the development of its pipeline, expand its platforms for gene editing and delivery, as well as to continue to strengthen its leading intellectual property portfolio.
Others: * On September 1, 2015, Intellia Therapeutics has closed a Series B investment round with $70 million in additional financing led by OrbiMed HealthCare Fund Management. Additional investors included Fidelity Management and Research Company, Janus Capital Management, Foresite Capital, Sectoral Asset Management, EcoR1 Capital and other leading mutual fund and healthcare investors. Founding investor Atlas Venture and Novartis also participated in the financing. In conjunction with the new financing, Carl L. Gordon, Ph.D., a founding Partner and Co-Head of Global Private Equity at OrbiMed, will join the Intellia Board of Directors.
Therapeutic area:
